Merck & Co., Inc. (BCBA:MRK)

Market Cap	300.24T
Revenue (ttm)	75.81T
Net Income (ttm)	19.55T
Shares Out	n/a
EPS (ttm)	7,728.34
PE Ratio	15.36
Forward PE	8.85
Dividend	575.38 (2.37%)
Ex-Dividend Date	Sep 15, 2025

Volume	3,317
Average Volume	4,541
Open	24,100
Previous Close	23,940
Day's Range	23,980 - 24,490
52-Week Range	16,950 - 29,650
Beta	0.38
RSI	71.66
Earnings Date	Oct 30, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD